[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Navamindradhiraj University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100592166",false,"NCT06989892","Comparing Super High-flux and High-flux Dialyzer Performance Among Hemodialysis Patient With Sepsis : a Randomized Control Trial","Inclusion Criteria:\n\n* ESKD patients who have sepsis condition with high interleukin-6 (IL-6 \\> 50 pg\u002Fml)\n\nExclusion Criteria:\n\n* Patients who needed dialysis with continuous kidney replacement therapy, vulnerable patient, include pregnant woman, patient who expected to pass away within the 24 hours.\n* Patients who have the history of allergic dialyzer reaction to dialyzer which used in this trial.","ALL","18 Years",{"count":17,"type":18},202,"ESTIMATED","INTERVENTIONAL",[21],"NA","Comparing the efficacy of superhigh-flux dialyzer with high-flux dialyzer in ESKD patient who have sepsis to improve mortality and sepsis outcome, an open label randomized control trial.",[24,25,26],"The Efficacy and Safety for Super High-flux Dialyzer in Case of Sepsis in ESKD","End Stage Kidney Disease (ESRD)","Sepsis",[28,29,30,31],"Superhighflux","hemodialysis","end stage kidney disease","sepsis","RECRUITING","2025-05-19",{"date":35,"type":36},"2025-05-25","ACTUAL",{"date":38,"type":36},"2024-07-25",{"date":40,"type":18},"2026-10-01",{"name":42,"class":43},"Navamindradhiraj University","OTHER",1,{"id":46,"slug":4,"hasResults":10,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":10,"sex":14,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":19,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":44},"100528768","NCT06165068","Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study","Inclusion Criteria:\n\n* Dry AMD with at least 1 large drusen. According to the AREDS study, large drusen have a size of more than 125 micron.\n* Patients can evaluate SD-OCT (Spectral domain optical coherence tomography), OCT angiography, and best-corrected visual acuity.\n* Age range: 50-85 years\n* Patients who have previously used antiplatelet drugs.\n\nExclusion Criteria:\n\n* Patient with advanced AMD, such as geographic atrophy, neovascular complications (choroidal neovascularization)\n* Patient with additional retinal diseases that affect visual acuity, e.g., retinal detachment, diabetic macular edema.\n* Patient with a history of intravitreal anti-VEGF injection or macular laser.\n* Patient using SSRIs, SNRIs, azole, NSAIDs, dual antiplatelet, anticoagulant medications.","50 Years","85 Years",{"count":53,"type":18},174,[55],"PHASE3","The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg\u002Fday or clopidogrel 75 mg\u002Fday) with or without a combination of antioxidants (N-acetylcysteine 600 mg\u002Fday) in a dry AMD patient with large drusen.\n\nParticipants will divided in to three groups.\n\n* Participants who were already taking low dose antiplatelet medications.\n* Participants who take the antiplatelet drug mentioned above in addition to the antioxidant prescribed by the investigator\n* Participants does not use any medications.",[58],"Dry Age-related Macular Degeneration","2023-12-11",{"date":61,"type":36},"2023-12-15",{"date":63,"type":18},"2023-12",{"date":65,"type":18},"2026-09",{"name":42,"class":43},""]